首页 > 市场调查报告书 > 製药

感染疾病

市场调查报告书

商品编码

1898691

通用感染疾病治疗市场规模、份额及成长分析（依疾病类型、治疗类型、给药途径、最终用户及地区划分）－2026-2033年产业预测

Zoonotic Disease Treatment Market Size, Share, and Growth Analysis, By Disease Type (Rabies, Lyme Disease), By Treatment Type (Vaccines, Antiviral Drugs), By Administration Route, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月26日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计到 2024 年，通用感染疾病治疗市场规模将达到 442.3 亿美元，到 2025 年将达到 469.7 亿美元，到 2033 年将达到 760 亿美元，预测期（2026-2033 年）的复合年增长率为 6.2%。

市场分析显示，通用感染疾病（即动物传染给人类的疾病）每年影响众多美国人，而都市化和人口成长加剧了这个问题。都市区卫生条件差进一步增加了患病风险。对动物性蛋白质的需求不断增长，以及动物脂肪摄取量的增加，都可能增加通用感染疾病的风险。此外，宠物饲养的增加虽然带来了陪伴，但也带来了媒介传播疾病的潜在健康风险。然而，发展中地区意识不足以及高昂的研发成本等挑战可能会阻碍市场成长。儘管如此，针对动物健康需求的新型药物的进步有望推动全球通用感染疾病治疗市场投资和创新，从而促进市场成长。

通用感染疾病治疗市场驱动因素

通用感染疾病治疗市场受多种因素驱动，包括人们对通用感染疾病流行情况及其传播途径的认识不断提高。创新有效治疗方法的推出，以及政府为对抗这些疾病所采取的支持措施，在市场扩张中发挥关键作用。此外，技术进步和研发投入的激增也显着促进了市场成长。这些因素共同创造了一个充满活力的环境，推动了通用感染疾病治疗技术的进步，同时也凸显了应对人畜共患病防控挑战的紧迫性。

限制通用感染疾病治疗市场的因素

儘管通用感染疾病治疗市场具有巨大的成长潜力，但许多挑战可能会阻碍其发展。主要因素包括有效治疗方法方案有限、治疗成本不断上涨、研发投入不足。学名药的出现和品牌药专利到期可能会进一步减缓市场成长。此外，熟练专业人员短缺和医疗基础设施不足，尤其是在开发中国家，也构成了该行业的障碍。研发所需的大量资金，加上民众对通用感染疾病的认知不足，都对市场发展构成重大阻碍。

通用感染疾病药物市场趋势

受全球日益增强的防范意识和积极应对日益增多的通用感染疾病的倡议推动，通用感染疾病治疗市场正经历显着增长。都市化、气候变迁和栖地破坏等因素加剧了这些疾病的出现和传播，促使人们增加对创新治疗方法和疫苗研发及推广的投资。此外，生物技术和基因工程的进步也带来了更有效的治疗方案。随着医疗卫生系统将预防疾病爆发和控制通用感染疾病的影响作为优先事项，并加强公共卫生、製药和环境机构之间的合作，预计该市场将显着扩张。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

GlaxoSmithKline plc（UK）
Pfizer Inc.（USA）
Merck & Co., Inc.（USA）
Novartis AG（Switzerland）
Johnson & Johnson（USA）
F. Hoffmann-La Roche AG（Switzerland）
AstraZeneca plc（UK）
Bayer AG（Germany）
Eli Lilly and Company（USA）
AbbVie Inc.（USA）
Gilead Sciences, Inc.（USA）
Bristol-Myers Squibb Company（USA）
Takeda Pharmaceutical Company Limited（Japan）
Boehringer Ingelheim GmbH（Germany）
BioNTech SE（Germany）
Moderna, Inc.（USA）
Inovio Pharmaceuticals, Inc.（USA）
Emergent BioSolutions Inc.（USA）

结论与建议

简介目录

Product Code: SQMIG35I2117

Zoonotic Disease Treatment Market size was valued at USD 44.23 Billion in 2024 and is poised to grow from USD 46.97 Billion in 2025 to USD 76 Billion by 2033, growing at a CAGR of 6.2% during the forecast period (2026-2033).

Market insights reveal that the incidence of zoonotic diseases transmitted from animals to humans affects a significant number of Americans annually, a concern exacerbated by urbanization and population growth. Poor sanitation in urban areas further heightens this risk. The rising demand for animal proteins may increase the risk of zoonotic infections due to higher consumption of animal fats. Additionally, pet ownership is on the rise, providing companionship but also introducing potential health risks from diseases carried by animals. However, challenges such as limited awareness in developing regions and high R&D costs may hinder market growth. Still, the global zoonotic disease treatment market stands to gain from advancements in novel medications tailored for animal health needs, paving the way for increased investment and innovation.

Top-down and bottom-up approaches were used to estimate and validate the size of the Zoonotic Disease Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Zoonotic Disease Treatment Market Segments Analysis

Global Zoonotic Disease Treatment Market is segmented by Disease Type, Treatment Type, Administration Route, End User and region. Based on Disease Type, the market is segmented into Rabies, Lyme Disease, Zika Virus, West Nile Virus, Hantavirus, Malaria, Tuberculosis, Relapsing Fever, Viral Hepatitis and Others. Based on Treatment Type, the market is segmented into Vaccines, Antiviral Drugs, Antibiotics, Immunoglobulins, Antibacterial Medication, Antifungal Medication and Others. Based on Administration Route, the market is segmented into Intravenous, Intramuscular and Oral. Based on End User, the market is segmented into Hospitals, Ambulatory Surgical Centers, Homecare Settings, Research Institutions and Clinics. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Zoonotic Disease Treatment Market

The zoonotic disease treatment market is propelled by a variety of factors, including the growing prevalence of zoonotic diseases and heightened awareness regarding their transmission. The introduction of innovative and effective treatment options plays a crucial role in this market's expansion, alongside supportive government initiatives aimed at combating these diseases. Additionally, advancements in technology and a surge in research and development investments significantly contribute to market growth. Together, these elements create a dynamic environment that fosters progress in the treatment of zoonotic diseases, highlighting the urgent need to address the challenges associated with their management and prevention.

Restraints in the Zoonotic Disease Treatment Market

Despite the considerable growth potential in the Zoonotic Disease Treatment market, various challenges could impede progress. Key factors include the limited availability of effective treatment options, prohibitive treatment costs, and insufficient investment in research and development. The advent of generic medications and the expiration of patents on branded drugs may further slow market growth. Additionally, the industry confronts obstacles due to a shortage of skilled professionals and inadequate healthcare infrastructure, particularly in developing countries. High capital requirements for research and development, coupled with a lack of public awareness about zoonotic diseases, pose significant barriers to the market's advancement.

Market Trends of the Zoonotic Disease Treatment Market

The Zoonotic Disease Treatment market is experiencing notable growth, fueled by a surge in global awareness and proactive measures against the rising prevalence of zoonotic diseases. Factors such as urbanization, climate change, and habitat disruption are contributing to the emergence and spread of these diseases, prompting increased investment in research, development, and deployment of innovative treatments and vaccines. Additionally, advancements in biotechnology and genetic engineering are paving the way for more effective therapeutic solutions. As healthcare systems prioritize preventing outbreaks and managing zoonotic disease impacts, the market is poised for significant expansion, fostering collaboration between public health, pharmaceutical, and environmental entities.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies

Global Zoonotic Disease Treatment Market Size by Disease Type & CAGR (2026-2033)

Market Overview
Rabies
Lyme Disease
Zika Virus
West Nile Virus
Hantavirus
Malaria
Tuberculosis
Relapsing Fever
Viral Hepatitis
Others

Global Zoonotic Disease Treatment Market Size by Treatment Type & CAGR (2026-2033)

Market Overview
Vaccines
Antiviral Drugs
Antibiotics
Immunoglobulins
Antibacterial Medication
Antifungal Medication
Others

Global Zoonotic Disease Treatment Market Size by Administration Route & CAGR (2026-2033)

Market Overview
Intravenous
Intramuscular
Oral

Global Zoonotic Disease Treatment Market Size by End User & CAGR (2026-2033)

Market Overview
Hospitals
Ambulatory Surgical Centers
Homecare Settings
Research Institutions
Clinics

Global Zoonotic Disease Treatment Market Size & CAGR (2026-2033)

North America (Disease Type, Treatment Type, Administration Route, End User)
- US
- Canada
Europe (Disease Type, Treatment Type, Administration Route, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Disease Type, Treatment Type, Administration Route, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Disease Type, Treatment Type, Administration Route, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Disease Type, Treatment Type, Administration Route, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Inovio Pharmaceuticals, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Emergent BioSolutions Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments